Compare American Financial Group Inc (AFG) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Financial Group Inc vs Gilead Sciences, Inc. — how do they compare? American Financial Group Inc trades at $144.22 (market cap $11.97B), while Gilead Sciences, Inc. trades at $136 (market cap $168.35B). The key difference: Gilead Sciences, Inc. is far larger — about 14.1× American Financial Group Inc's market cap, and American Financial Group Inc pays the higher dividend (2.44%). Which is the better fit depends on your goals.
| AFG | GILD | |
|---|---|---|
Market Cap | $11.97B | $168.35B |
Sector | Financials | Health |
52-Week High | $148.71 | $155.80 |
52-Week Low | $124.18 | $110.56 |
Enterprise Value | $12.35B | $191.42B |
Dividend Yield | 2.44% | 2.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AFG trades at $142.77, down 0.76% on the day, with a bullish technical signal supported by moving averages and a neutral RSI near 59. The stock shows consistent profitability with a net income margin of 11.66% and ROE of 20.41%, though revenue dipped slightly in 2025. Recent Q2 2026 earnings beat estimates, driven by strong P&C underwriting and investment income, as reported by Business Wire on August 4, 2026.
The outlook remains positive with a consensus price target of $160.67, implying 12.5% upside. Risks include potential earnings volatility and competitive pressures in the insurance sector. Analyst sentiment is mixed with 41% buy ratings, but no sell recommendations, supporting a cautiously optimistic view for long-term investors.
Gilead Sciences (GILD) trades at $133.06, down slightly by 0.11% today, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 revenue growth of 8% year-over-year, beating estimates, though a net loss of $6.75 per share resulted from acquisition-related costs. Analyst consensus is strongly bullish with a $151.22 price target, and recent news highlights robust HIV drug sales and pipeline progress.
The outlook for GILD is positive, driven by raised 2026 guidance and HIV franchise strength, but risks include patent cliffs by the mid-2030s and integration challenges from acquisitions. Investors should weigh the high valuation multiples against growth potential, with the stock offering upside if execution continues to exceed expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About American Financial Group Inc
American Financial Group Inc is a holding company that is engaged primarily in property and casualty insurance services. The company has a focus on specialized commercial products for businesses. American also has annuity operations that are focused on sales of traditional fixed and fixed-indexed annuities in the education, bank, and individual markets. American's insurance operations are conducted through the Great American Insurance Group. The group writes business in all 50 of the United States, primarily through independent agents and brokers.
Read more on AFG →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
